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Background: Tidal expiratory flow limitation (EFL
T
) is frequently found in patients with 
COPD and can be detected by forced oscillations when within-breath reactance of a single-
breath is $0.28 kPa⋅s⋅L−1. The present study explored the association of within-breath reactance 
measured over multiple breaths and EFL
T
 with 6-minute walk distance (6MWD), exacerbations, 
and mortality.
Methods: In 425 patients, spirometry and forced oscillation technique measurements were 
obtained on eight occasions over 3 years. 6MWD was assessed at baseline and at the 3-year 
visit. Respiratory symptoms, exacerbations, and hospitalizations were recorded. A total of 5-year 
mortality statistics were retrieved retrospectively. We grouped patients according to the mean 
within-breath reactance (∆Xrs), measured over several breaths at baseline, calculated as mean 
inspiratory–mean expiratory reactance over the sampling period. In addition to the established 
threshold of EFL
T
, an upper limit of normal (ULN) was defined using the 97.5th percentile 
of ∆Xrs of the healthy controls in the study; 6MWDs were compared according to ∆Xrs, as 
normal, $ ULN , EFL
T
, or $ EFL
T
. Annual exacerbation rates were analyzed using a negative 
binomial model in the three groups, supplemented by time to first exacerbation analysis, and 
dichotomizing patients at the ULN.
Results: In patients with COPD and baseline ∆Xrs below the ULN (0.09 kPa⋅s⋅L−1), 6MWD 
was stable. 6MWD declined significantly in patients with ∆Xrs $ ULN. Worse lung function 
and more exacerbations were found in patients with COPD with ∆Xrs $ ULN, and patients 
with ∆Xrs $ ULN had shorter time to first exacerbation and hospitalization. A significantly 
higher mortality was found in patients with ∆Xrs $ ULN and FEV
1
 .50%.
Conclusion: Patients with baseline ∆Xrs $ ULN had a deterioration in exercise perfor-
mance, more exacerbations, and greater hospitalizations, and, among those with moderate 
airway obstruction, a higher mortality. ∆Xrs is a novel independent marker of outcome in 
COPD.
Keywords: forced oscillation technique, reactance, COPD, exacerbations, 6-minute walk test, 
mortality
Introduction
COPD is a major cause of morbidity and mortality, leading to an estimated 3.1 million 
deaths globally in 2012.1 Although symptoms and exacerbation rate have been added 
to our assessment system of COPD,2 spirometry remains an important tool in assessing 
severity and prognosis in this disease. Changes in the forced expiratory volume in 1 
second (FEV
1
) are still the best indicator of disease progression and the risk of dying 
from COPD.2,3 Yet, on an individual level, FEV
1
 is an unreliable marker of morbidity, 
especially in early disease,4–6 and there is a need to identify alternative objective tests 
that can aid in stratifying the risk of further patient deterioration.
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Patients who exhibit tidal expiratory flow limitation 
(EFL
T
) might be such a subgroup. EFL
T
 occurs when increases 
in driving pressure fail to increase expiratory flow during 
resting tidal breathing and is most often seen in patients with 
severe COPD,7,8 although it can occur with only moderate 
airway obstruction. Previous studies of EFL
T
 in COPD have 
focused on its association with operating lung volume, exer-
cise tolerance,9,10 and its relation to breathlessness.11–13 It is 
not known whether EFL
T
 can provide longer-term prognostic 
information in COPD.
EFL
T
 can be detected by the forced oscillation technique 
(FOT).14,15 When peripheral airways collapse on expiration, 
oscillatory pressure signals are prevented from reaching 
the alveoli. As this happens, the oscillatory compliance is 
reduced. Consequently, expiratory reactance (Xrs
exp
) becomes 
more negative than the inspiratory reactance (Xrs
insp
), lead-
ing to a within-breath reactance difference (∆Xrs). In the 
absence of EFL
T
, reactance measured in inspiration and in 
expiration is almost identical. The within-breath reactance 
difference (∆Xrs) cut-off of 0.28 kPa⋅s⋅L−1 has been defined 
and validated to identify flow-limited breaths.14,15 EFL
T
 is 
not only linked to dyspnea in COPD,11,16 but also to COPD 
exacerbations, where ∆Xrs have been found to increase at 
the onset of COPD exacerbations and decrease when the 
exacerbation resolves.17
In this study, we used forced oscillation technique to 
define EFL
T
 in 425 patients with COPD. We hypothesized 
that the presence of EFL
T
, assessed by increased mean ∆Xrs 
(∆Xrs), would relate to changes in 6MWD, the risk of COPD 
exacerbations, and, possibly, mortality. We explored these 
hypotheses using baseline ∆Xrs as a predictor for future 
events. Patients with COPD with abnormally high ∆Xrs, 
both above the upper limit of normal (ULN) and above the 
established threshold of EFL
T
, were investigated to determine 
whether they differed from those without evidence of tidal 
expiratory flow limitation.
Methods
study design and patients
The current data derive from the Bergen cohort of the 
Evaluation of COPD Longitudinally to Identify Predictive 
Surrogate Endpoints (ECLIPSE) study,18 with additional 
patients enrolled from our clinical catchment area. Written 
informed consent was obtained from all study subjects. 
The study was approved by the regional ethics committee, 
REK vest (REK 165.08), and performed in accordance 
with the Declaration of Helsinki and the Good Clinical 
Practice guidelines (ClinicalTrials.gov; No: NTC00292552; 
www.ClinicalTrials.gov).39
Inclusion criteria for patients with COPD were: age 
40–75 years, FEV
1
 ,80% predicted, FEV
1
/FVC ,0.7, and 
a smoking history of $10 pack-years. Study patients were 
evaluated every 6 months for 3 years with an additional visit 
at 3 months after baseline, totaling eight visits. The American 
Thoracic Society-Division of Lung Disease (ATS-DLD-78) 
questionnaire and the modified Medical Research Council 
dyspnea scale score (mMRC) were used to record respira-
tory symptoms.19,20
Post-bronchodilator spirometry and oscillatory lung mechan-
ics during tidal breathing were performed after inhalation of 
0.4 mg salbutamol (GlaxoSmithKline, Ventolin, London, UK) 
according to American Thoracic Society/European Respiratory 
Society (ATS/ERS) international standards at each visit using 
a Jaeger MasterScope CT Impulse Oscillation System (Jaeger, 
Hoechberg, Germany).21,22 Local reference values were used 
to determine the FEV
1
% predicted.23 The FOT measurements 
were performed with the patient seated, cheeks supported, and 
wearing a nose clip. We performed three continuous measure-
ments of 30 seconds, totaling 90 seconds of tidal volume breath-
ing. Acceptability of measurements was determined using the 
ERS 2003 task force recommendations.22
∆Xrs reactance was averaged over the 90-second sample, 
containing several breaths, and was calculated as follows: 
∆Xrs = mean Xrs
insp
 at 5 Hz – mean Xrs
exp
 at 5 Hz. Two 
cut-offs were investigated: the ULN defined as the 97.5th 
percentile of healthy controls in the Bergen cohort of the 
ECLIPSE study (∆Xrs $0.09 kPa⋅s⋅L−1; Figure S1),13 and at 
the established EFL
T
 defining threshold for within-breath reac-
tance, 0.28 kPa⋅s⋅L−1, derived from single-breath analysis.14,15 
To illustrate the variability of our multiple-breath measure-
ment, ∆Xrs was plotted against time in a subset of the patients 
defined EFL
T
 at baseline with complete visits (N=20).
study outcomes
Distance walked during the 6-minute walk test (6MWT) 
was used to assess exercise performance. The 6MWT was 
supervised by a trained technician and performed in a 30-m, 
straight hospital corridor according to agreed standards at 
baseline and at the end of the study, at the 3-year visit.24
Exacerbations were defined as a worsening of respiratory 
symptoms over 2 days or more that required systemic corti-
costeroids or antibiotics, alone or in combination (“moderate 
exacerbations”), or exacerbations resulting in hospitaliza-
tion (“severe exacerbations”). Assessment of exacerbations 
was performed retrospectively by the study physician at the 
half-yearly visits, over the 3-year study period.
Mortality statistics were retrieved on August 25, 2011, 
approximately 5 years after the conclusion of the baseline 
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visit by checking vital status in our local patient file system, 
which is linked to the Norwegian Causes of Death Registry. 
The Causes of Death Registry includes deaths of all residents, 
regardless of whether they die in Norway or abroad, and is 
assumed to have information on .98% of all deaths.25
statistics
IBM SPSS version 22, Stata 13.1, and R 3.2.3 GUI 1.66 were 
used for different aspects of statistical analyses. Data are 
presented as mean ± standard deviation, median (quartiles), 
mean (95% confidence interval), and absolute count or per-
centage. Means were compared using independent samples 
t-tests, paired samples t-tests, or Mann–Whitney U test when 
appropriate.
Patients were categorized into three groups according 
to ∆Xrs: normal, $ ULN , EFL
T
, and $ EFL
T
 at baseline. 
We report the change in the 6-minute walk distance in these 
three groups from baseline to the 3-year visit in notched 
boxplots. Differences in walking distance between baseline 
and the end of the study were compared using paired samples 
t-test, grouping the patients according to the ∆Xrs and the 
Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) grade.2
The rate of exacerbations in the three groups was analyzed 
as suggested by Keene et al using a negative binomial 
regression model, accounting for the yearly variability among 
test subjects in the exacerbation rate over the 3-year study 
period, adjusting for FEV
1
, age, sex, and a binary classifier 
identifying frequent exacerbators in the year prior to inclusion.26 
Parameter effects of the baseline explanatory variables are 
reported as annual rate ratios (RRs), 95% confidence interval 
(CI), and P-values. Moderate and severe exacerbations 
requiring hospitalization were also investigated on the basis 
of the occurrence of ∆Xrs $ ULN at baseline by time to first 
event analysis. Groups were compared using a log-rank test. 
Results are displayed as 1-minus-survival plots.
Survival analysis was performed with Kaplan–Meier 
survival analysis, comparing distributions with the log-
rank test, grouping patients by the occurrence of ∆Xrs $ 
ULN at baseline, and by dichotomizing FEV
1
 at 50% of 
that predicted.
Results
Baseline characteristics
In this population of patients with COPD, 60% were men 
and had moderate to very severe airway obstruction. Women 
were, on average, 2 years younger and had lower tobacco 
exposure (Table S1); 50% of patients with COPD had 
normal ∆Xrs, 31% were classified as being abnormal 
with ∆Xrs $ ULN , EFL
T
, and 18% had ∆Xrs above the 
threshold of EFL
T
 (Table 1). From the normal to the abnor-
mal group, lung function worsened with a decline in FEV
1
 
and FVC, and an increase in body mass index (BMI) and 
mMRC. This difference was most marked between the 
normal and EFL
T
 group. For IC, we only found a significant 
difference between the normal and the EFL
T
 group.
Table 1 Baseline characteristics in COPD patients with different levels of ∆Xrs (n=425)
Subject characteristics Normal Abnormal EFLT
∆Xrs , ULN ULN $∆Xrs , EFLT ∆Xrs .0.28 kPa⋅s⋅L−1
subjects (n) 213 (50%) 134 (32%) 78 (18%)
Women 40% 36% 49%
age (years) 63 (7) 64 (7) 63 (6)
BMI kg/m2 24 (5)c,d 26 (5)c,e 28 (6)d,e
Pack-years (years) 40 (24) 43 (22) 39 (22)
Frequent exacerbators (%) 13% 20% 35%
mMrC 1.2 (0, 2)c,d 1.8 (0.25, 2)c,e 2.3 (1, 2)d,e
FeV1 (l) 1.7 (0.5)
c,d 1.3 (0.5)c,e 1.1 (0.4)d,e
FeV1 (%) 52 (11)
c,d 42 (12)c 38 (13)d
FVC (l) 3.5 (0.9)c,d 3.2 (0.8)c,e 2.8 (0.9)d,e
IC (l) 2.6 (0.8)d 2.5 (0.7) 2.3 (0.7)d
IC (%) 88 (19) 85 (20) 84 (21)
6MWD (meters) 455 (102)c,d 410 (109)c,e 363 (110)d,e
estimated exacerbations per yeara 0.7 1.3 1.6
Deathsb 25 (12)c,d 28 (21)c 18 (23)d
Notes: Data presented as mean ± standard deviation unless otherwise stated. aestimated exacerbation rate by negative binomial model. bnumber of deaths at the 5-year 
census (%). Significant differences at the 5% level are marked as cbetween normal and abnormal, dbetween normal and eFlT, and 
ebetween abnormal and eFlT. pack-years: 
packs of 20 cigarettes smoked per day × years as a smoker; Frequent exacerbators: percentage with $2 exacerbations the year the prior to inclusion.
Abbreviations: Uln, upper limit of normal 0.09 kPa⋅s⋅l−1; eFlT, tidal expiratory flow limitation; BMI, body mass index; mMRC, modified Medical Research Council dyspnea 
scale score – mean (quartiles); FeV1, forced expiratory volume in 1 second; FeV1 (%), FeV1 percentage of predicted; FVC, forced vital capacity; IC, inspiratory capacity; IC (%), 
IC percentage of predicted; ∆Xrs, difference between mean inspiratory and mean expiratory reactance at 5 hz over multiple breaths; 6MWD, 6-minute walk distance.
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∆Xrs was not a stable measurement. Many patients 
defined as EFL
T
 at baseline fell below the EFL
T
 threshold 
during the course of the study (Figure 1). Six percent of the 
consequent ∆Xrs measurements were found to be normal; 
23% of the patients dropped out of the study before the 
final visit, the main reason being death during the study 
period (Table 2).
relationship of eFlT to study outcomes
∆Xrs was as poorly correlated with baseline 6-minute 
walking distance as FEV
1
 (Figure 2A and B). On a group 
level, 6MWD declined with increasing ∆Xrs, being 455 m in 
the normal, 410 m in the abnormal, and 363 m in the EFL
T
 
group (Table 1). In patients who completed both the base-
line and the final visit, changes in 6MWD were compared. 
No significant change between the baseline and the final 
3-year visit was seen in the 6MWD of patients with normal 
∆Xrs. Patients with ∆Xrs $ ULN declined by a mean of 
37 m (95% CI 15–58), P=0.001, and patients with EFL
T
 
declined by 63 m (95% CI 31–95), P,0.001 (Figure 2C). 
Grouping by GOLD grade produced similar boxplots. GOLD 
2 patients remained stable whereas a significant decline was 
seen in GOLD 3–4 grades (Figure 2D).
A total of 1,289 moderate to severe exacerbations were 
recorded throughout the study. By negative binomial 
regression, estimated annual exacerbations rates were 0.7 
in patients with normal ∆Xrs, 1.3 in patients with COPD 
with ∆Xrs $ ULN, and 1.6 in patients with EFL
T
. Annual 
exacerbation RR compared to the normal group was 1.28 for 
ULN patients and 1.30 for EFL
T
 patients (Table 3). A time 
to first exacerbation analysis was performed in patients 
with COPD with and without evidence of ∆Xrs $ ULN at 
baseline. Significant differences were found in both time to 
first exacerbation (P=0.009) and in time to first hospitaliza-
tion (P=0.017; Figure 3A). Median time to first moderate or 
severe exacerbation was 76 weeks in patients with COPD 
with normal ∆Xrs, compared with only 55 weeks in COPD 
patients with ∆Xrs $ ULN at baseline (Table 4). The time 
until 25% of the patients were hospitalized was 126 weeks 
in patients with normal ∆Xrs and 72 weeks in patients 
with ∆Xrs $ ULN.
Mortality
At the 5-year census, 72 (17%) of the 425 patients with 
COPD had died. Deaths were significantly more frequent 
in patients with $ ULN than in patients with normal ∆Xrs, 
but not significantly different between the $ ULN and the 
EFL
T
, groups (Table 1). Mortality was higher in patients with 
FEV
1
 ,50% (Figure 4). The difference in mortality between 
patients with ∆Xrs in the normal range and $ ULN was 
driven by increased mortality in patients with FEV
1
 .50% 
(Figure 4). Mortality was 17% in ∆Xrs $ ULN patients with 
FEV
1
 .50%, compared to 5% in patients with normal ∆Xrs 
(P,0.001; Figure 4). Mortality in patients with ∆Xrs $ ULN 
was similar to what was found in patients with COPD with 
much more advanced airway obstruction.
Discussion
Using data from the ECLIPSE study, we investigated associa-
tions between increased ∆Xrs at the ULN and at the threshold 
of EFL
T
 with decline in 6MWD, risk of later exacerbations, 
and all-cause mortality. No change in 6MWD was found 
in patients with COPD with ∆Xrs in the normal range. All 
patients with COPD with ∆Xrs $ ULN deteriorated signifi-
cantly in 6MWD. Patients with COPD with ∆Xrs $ ULN had 
increased risk for both moderate and severe exacerbations, 
and, in the patients with only moderate airway obstruction, 
FEV
1
 .50%, a significantly higher mortality. This study 
Figure 1 Timeplot illustrating the variability of ∆Xrs measurements (splines) over 
the course of the study shown in the first 20 patients with COPD with complete 
visits, defined as having EFLT at baseline (∆Xrs $0.28 kPa⋅s⋅l−1). The dotted line is 
set at 0.09 kPa⋅s⋅l−1, the upper limit of normal and the solid line at eFlT.
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Table 2 Deaths and dropouts during the 3-year study period 
(n=96)
Reason N %
Died 41 10
FOT not performed at the final visit 16 4
refused further participation 8 2
excluded due to use of oral steroids 8 2
excluded after being diagnosed with pulmonary cancer 5 1
Other causes 18 4
Total 96 23
Abbreviation: FOT, forced oscillation technique.
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demonstrates that ∆Xrs provides valuable extra information 
in addition to FEV
1
 when characterizing the effects of small-
airway obstruction on key COPD outcomes.
We defined the ULN at the 97.5th percentile of healthy 
controls included in our study. Data describing the control 
group have previously been published.13,18 The FOT threshold 
identifying a single flow-limited breath has been defined 
when within-breath reactance was .0.28 kPa⋅s⋅L−1.14,15 
We interpreted our continuous spectrum measurements 
performed over several breaths as showing evidence of 
flow limitation when measurements between the ULN 
and the threshold of EFL
T
 were found. These borderline 
measurements are thought to represent a mixture of normal 
and flow-limited breaths.
Exercise limitation is extremely common in COPD, and 
even small decreases in the 6MWD over time identify patients 
with increased risks of dying.27 When EFL
T
 is present, 
patients can only increase their minute ventilation during 
exercise by increasing breathing frequency or by dynamic 
hyperinflation, allowing end-expiratory lung volume to 
rise.28 Dynamic hyperinflation can be induced by self-paced 
walking exercise. This is usually assessed by changes in 
Figure 2 (A) six-minute walk distance (6MWD) in patients with COPD (n=388) at different levels of FeV1% predicted (A) and ∆Xrs (B) at baseline. Dotted lines set at 
350 m (horizontal) and at ∆Xrs =0.09 kPa⋅s⋅l−1, upper limit of normal (Uln), and ∆Xrs =0.28 kPa⋅s⋅l−1, the threshold for tidal expiratory flow limitation (EFLT). The solid lines 
represent the regression lines. (C) 6MWT at baseline and the 3-year visit presented by notchplots with quartiles, 95% central range and outliers among COPD patients of 
gOlD II–IV grades and categorized according to ∆Xrs (D) as normal (white), below eFlT, but above Uln (light gray), and . eFlT threshold (gray). non-overlapping notched 
areas are likely to represent significant differences between groups. Solid lines are drawn between the mean 6MWD at baseline and the 3-year visit.
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operating lung volume.12,29 We did not measure lung volume 
during the 6MWT, but reasoned that patients with COPD 
showing evidence of flow limitation at baseline, either as 
having ∆Xrs $ ULN or the threshold of EFL
T
, were more 
likely to have a worse exercise tolerance at the same visit. 
This was true on a group level. The EFL
T
 group had the 
lowest 6MWD, but neither FEV
1
 % predicted nor any cut-off 
level of ∆Xrs could identify patients with COPD with a short 
walking distance (,350 m), as proposed by Spruit et al.30 
No significant decline was seen in patients with ∆Xrs in the 
normal range; in patients with COPD with ∆Xrs $ ULN, 
it declined 37 m, and in patients with EFL
T
, it declined by 
63 m. The minimal clinically important difference on an 
individual level has been suggested to be 30 m in an ERS/
ATS systematic review;31 consequently, the differences seen 
over time between our subgroups defined by ∆Xrs $ ULN 
and EFL
T
 are likely to be clinically important.
Exacerbation and hospitalization rates at our site were 
similar to those reported in the completed ECLIPSE study 
and in the TORCH study.32,33 By negative binomial regres-
sion, the ∆Xrs cut-offs $ ULN and EFL
T
 were both signifi-
cant predictors for higher rates of exacerbations with very 
similar RR, demonstrating that the increased risk of exacer-
bations by EFL
T
 is identified already at ULN. In the time to 
first event analysis of patients with ∆Xrs $ ULN, we found 
a shorter time to first exacerbation and a shorter time to first 
hospitalization than that of the COPD patients with ∆Xrs in 
the normal range. A previous study on hospitalized patients 
showed that many, but not all, have FOT-defined EFL
T
 during 
a COPD exacerbation.17 FOT measurements performed 
during hospitalized COPD exacerbations show that ∆Xrs 
measurements improve during resolution of an exacerba-
tion, although many patients remain EFL
T
 at discharge.17 
At present, there is a shortage of readily measurable bio-
markers that can predict the risk of future exacerbations. 
Our data suggest that, after adjusting for lung function and 
exacerbation history, EFL
T
 measurement can identify patients 
who are more likely to develop exacerbations. Further pro-
spective studies to confirm these observations and explore 
their mechanism are merited.
Patients with COPD with an FEV
1
 .50% predicted and 
evidence of EFL
T
, defined as baseline ∆Xrs $ ULN, had signifi-
cantly higher risk of dying within the 5-year follow-up. Similar 
associations were not found in the patients with more advanced 
Table 3 annual rate ratios estimated by negative binomial 
regression (n=395)
Baseline explanatory variables RR 95% CI P-value
∆Xrs
$Uln (0.09 kPa⋅s⋅l−1) and ,eFlT 1.28 1.05, 1.55 0.011
$eFlT (0.28 kPa⋅s⋅l−1) 1.30 1.05, 1.64 0.009
FeV1 % predicted 0.07 0.04, 0.14 ,0.001
age in decades 1.36 1.06, 1.34 0.009
sex (male) 0.85 0.72, 1.00 0.048
exacerbation in the year prior to inclusion
$2 1.99 1.64, 2.41 ,0.001
Intercept 0.98 0.42, 2.27 0.965
Abbreviations: RR, estimated rate ratio; 95% CI, confidence interval; ULN, upper 
limit of normal 0.09 kPa⋅s⋅l−1; eFlT, tidal expiratory flow limitation; FEV1, forced 
expiratory volume in 1 second; FeV1 (%), FeV1 percentage of predicted.
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Figure 3 Time to first moderate or severe exacerbation (A) and to the first hospitalization (B) in COPD patients with ∆Xrs measurements above the upper limit of normal 
(Uln), 0.9 kPa⋅s⋅l−1 (solid line), and below the Uln at the baseline visit. Dashed line at 25%.
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airway obstruction and FEV
1
 ,50%. However, COPD is a 
complex, heterogeneous disease, and respiratory impairment 
is associated with higher incidence of comorbidities, such as 
hypertension, cardiovascular disease, and diabetes.34 If there 
is an association between ∆Xrs and mortality, the higher risk 
of adverse outcomes associated with comorbid disease could 
mask such an association with advanced disease. Although the 
association between death and ∆Xrs was highly significant, 
this sub-analysis should be interpreted with caution due to the 
relatively small number of deaths in patients with FEV
1
 .50% 
predicted (Table 1).
There are certain limitations of this study. The FOT 
threshold identifying a single flow-limited breath has been 
defined at ∆Xrs .0.28 kPa⋅s⋅L−1.14,15 It is not known whether 
the use of this threshold may lead to different results when 
applied to values measured over a continuous spectrum of 
several breaths. Previously published data show that the 
end-expiratory lung volume varies from breath-to-breath, 
affecting the prevalence of EFL
T
.8,15 Although the prevalence 
of EFL
T
 increased as the FEV
1
% predicted declined, not all 
patients with very severe airway obstruction were found to 
have EFL
T
. In previous studies on elderly and COPD with 
the NEP technique, higher prevalence of EFL
T
 have been 
reported than in the present study.11,35,36 Different inclusion 
criteria and differences in sensitivity between the NEP and 
the FOT technique, together with the possibility that in 
borderline patients the application of a NEP per se could 
lead to development of EFL
T
, are likely explanations. The 
wide reference range of FEV
1
 inevitably may also lead to 
an overestimation of the suspected lung function decline in 
many patients.23
As previously noted, EFL
T
 varies between breaths in 
many patients with COPD and varies with repeat testing, 
likely reflecting differences in the end-expiratory lung 
volume on different test days.13 Physiological variability in 
these measurements might require the repetition of this test 
in different periods to increase the sensitivity of our test. 
Despite this limitation, important relationships related to 
the presence of tidal flow limitation were seen, even when 
the data were controlled for severity of airflow obstruction 
measured by FEV
1
. The data reflect results from the largest 
recruiting center in the ECLIPSE study, in which patients 
were carefully characterized using standardized methodolo-
gies including oscillatory mechanics.18,37
Conclusion
Consistent differences in clinically relevant outcomes were 
found, such as exercise capability, exacerbations, hospitaliza-
tions, and death in COPD patients with baseline ∆Xrs beyond 
the ULN. This is below the established threshold for EFL
T
. 
Our data support previous studies showing that patients with 
EFL
T
 have worse lung mechanics than is evident from FEV
1
 
measurement alone.11,38 The present study suggests that 
evidence of EFL
T
, measured during tidal breathing in an 
effort-independent fashion, can identify a subgroup of COPD 
patients with worse clinical outcomes.
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Table 4 exacerbations, hospitalizations, and deaths in COPD 
patients with and without ∆Xrs $ Uln at baseline (n=425)
Parameter ∆Xrs , ULN ∆Xrs $ ULN
Total N 213 212
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76 (57, 95) 55 (42, 68)
log-rank test P=0.009
n patients (%) hospitalized 62 (29%) 84 (40%)
Time (weeks) until 25% of the 
patients were hospitalized
126 72
log-rank test P=0.017
n dead at 5-year follow-up 25 (12%) 46 (22%)
log-rank test P=0.011
Note: ULN defined at ∆Xrs $0.09 kPa⋅s⋅l−1.
Abbreviations: Uln, upper limit of normal 0.09 kPa⋅s⋅l−1; 95% CI, 95% confidence 
interval.
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Figure 4 Kaplan–Meier survival curves in COPD patients with normal ∆Xrs and in 
COPD patients with ∆Xrs measurements above the upper limit of normal (Uln). 
Test of equality of survival distributions was performed using log-rank test.
International Journal of COPD 2017:12submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2186
aarli et al
The work was performed at Haukeland University 
Hospital. The authors thank all participants who took part in 
the study, all members of the Bergen Respiratory Research 
Group who contributed to the data collection, and offer spe-
cial thanks to Lene Svendsen, Rita Oppedal, Tina Endresen-
Vinsjevik, and Eli Nordeide who performed/supervised the 
pulmonary function tests.
Author contributions
The corresponding author BBA wrote the manuscript, had 
access to all of the data in the study, and takes responsibility 
for the integrity of the data and the accuracy of the data 
analysis. PMAC was in the ECLIPSE Scientific Committee 
and PSB in the ECLIPSE Steering Committee. They both 
contributed to the development of the research design. PSB, 
JAH, and TMLE also contributed in the data collection. 
All authors, including RLJ and RD, contributed to the data 
analysis, the clinical interpretation of the data, and to review-
ing the final submission.
Disclosure
The authors report no conflicts of interest in this work.
References
 1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality 
from 235 causes of death for 20 age groups in 1990 and 2010: a sys-
tematic analysis for the Global Burden of Disease Study 2010. Lancet. 
2012;380(9859):2095–2128.
 2. From the Global Strategy for the Diagnosis, Management and Prevention 
of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
2017. Available from: http://goldcopd.org/gold-2017-global-strategy-
diagnosis-management-prevention-copd/. Accessed April 18, 2017.
 3. Soriano JB, Alfageme I, Almagro P, et al. Distribution and prognostic 
validity of the new Global Initiative for Chronic Obstructive Lung 
Disease grading classification. Chest. 2013;143(3):694–702.
 4. Franciosi LG, Page CP, Celli BR, et al. Markers of disease severity in 
chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2006; 
19(3):189–199.
 5. Gelb AF, Hogg JC, Müller NL, et al. Contribution of emphysema and 
small airways in COPD. Chest. 1996;109(2):353–359.
 6. Global Strategy for the Diagnosis, Management and Prevention of COPD, 
Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011. 
2011. Available from: www.goldcopd.org. Accessed January 2, 2012.
 7. Hyatt RE. The interrelationships of pressure, flow, and volume during 
various respiratory maneuvers in normal and emphysematous subjects. 
Am Rev Respir Dis. 1961;83:676–683.
 8. O’Donnell DE. Ventilatory limitations in chronic obstructive pulmonary 
disease. Med Sci Sports Exerc. 2001;33(7 Suppl):S647–S655.
 9. Calverley PM, Koulouris NG. Flow limitation and dynamic hyperin-
flation: key concepts in modern respiratory physiology. Eur Respir J. 
2005;25(1):186–199.
 10. Diaz O, Villafranca C, Ghezzo H, et al. Role of inspiratory capacity on 
exercise tolerance in COPD patients with and without tidal expiratory 
flow limitation at rest. Eur Respir J. 2000;16(2):269–275.
 11. Eltayara L, Becklake MR, Volta CA, Milic-Emili J. Relationship between 
chronic dyspnea and expiratory flow limitation in patients with chronic 
obstructive pulmonary disease. Am J Respir Crit Care Med. 1996; 
154(6 Pt 1):1726–1734.
 12. O’Donnell DE, Webb KA. Exertional breathlessness in patients with 
chronic airflow limitation. The role of lung hyperinflation. Am Rev 
Respir Dis. 1993;148(5):1351–1357.
 13. Aarli BB, Calverley PM, Jensen RL, Eagan TM, Bakke PS, Hardie JA. 
Variability of within-breath reactance in COPD patients and its associa-
tion with dyspnoea. Eur Respir J. 2015;45(3):625–634.
 14. Dellacà RL, Duffy N, Pompilio PP, et al. Expiratory flow limitation 
detected by forced oscillation and negative expiratory pressure. Eur 
Respir J. 2007;29(2):363–374.
 15. Dellacà RL, Santus P, Aliverti A, et al. Detection of expiratory flow 
limitation in COPD using the forced oscillation technique. Eur Respir J. 
2004;23(2):232–240.
 16. O’Donnell DE, Laveneziana P. Dyspnea and activity limitation in 
COPD: mechanical factors. COPD. 2007;4(3):225–236.
 17. Jetmalani K, Timmins S, Brown NJ, et al. Expiratory flow limitation 
relates to symptoms during COPD exacerbations requiring hospital 
admission. Int J Chron Obstruct Pulmon Dis. 2015;10:939–945.
 18. Vestbo J, Anderson W, Coxson HO, et al; ECLIPSE investigators. 
Evaluation of COPD longitudinally to identify predictive surrogate 
end-points (ECLIPSE). Eur Respir J. 2008;31(4):869–873.
 19. Mahler DA, Wells CK. Evaluation of clinical methods for rating dys-
pnea. Chest. 1988;93(3):580–586.
 20. Ferris BG. Epidemiology Standardization Project (American Thoracic 
Society). Am Rev Respir Dis. 1978;118(6 Pt 2):1–120.
 21. Standardization of spirometry, 1994 update. American Thoracic 
Society. Am J Respir Crit Care Med. 1995;152(3):1107–1136.
 22. Oostveen E, MacLeod D, Lorino H, et al; ERS Task Force on Respi-
ratory Impedance Measurements. The forced oscillation technique in 
clinical practice: methodology, recommendations and future develop-
ments. Eur Respir J. 2003;22(6):1026–1041.
 23. Gulsvik A, Tosteson T, Bakke P, Humerfelt S, Weiss ST, Speizer FE. 
Expiratory and inspiratory forced vital capacity and one-second forced 
volume in asymptomatic never-smokers in Norway. Clin Physiol. 2001; 
21(6):648–660.
 24. ATS Committee on Proficiency Standards for Clinical Pulmonary 
Function Laboratories. ATS statement: guidelines for the six-minute 
walk test. Am J Respir Crit Care Med. 2002;166(1):111–117.
 25. Pedersen AG, Ellingsen CL. Data quality in the Causes of Death Reg-
istry. Tidsskr Nor Laegeforen. 2015;135(8):768–770.
 26. Keene ON, Calverley PM, Jones PW, Vestbo J, Anderson JA. Statistical 
analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revis-
ited. Eur Respir J. 2008;32(1):17–24.
 27. Polkey MI, Spruit MA, Edwards LD, et al. Six-minute-walk test in 
chronic obstructive pulmonary disease: minimal clinically important dif-
ference for death or hospitalization. Am J Respir Crit Care Med. 2013; 
187(4):382–386.
 28. Guenette JA, Webb KA, O’Donnell DE. Does dynamic hyperinflation 
contribute to dyspnoea during exercise in patients with COPD? Eur 
Respir J. 2012;40(2):322–329.
 29. Marin JM, Carrizo SJ, Gascon M, Sanchez A, Gallego B, Celli BR. 
Inspiratory capacity, dynamic hyperinflation, breathlessness, and 
exercise performance during the 6-minute-walk test in chronic obstruc-
tive pulmonary disease. Am J Respir Crit Care Med. 2001;163(6): 
1395–1399.
 30. Spruit MA, Polkey MI, Celli B, et al; Evaluation of COPD Longitudinally 
to Identify Predictive Surrogate Endpoints (ECLIPSE) study investi-
gators. Predicting outcomes from 6-minute walk distance in chronic 
obstructive pulmonary disease. J Am Med Dir Assoc. 2012;13(3): 
291–297.
 31. Singh SJ, Puhan MA, Andrianopoulos V, et al. An official systematic 
review of the European Respiratory Society/American Thoracic Society: 
measurement properties of field walking tests in chronic respiratory 
disease. Eur Respir J. 2014;44(6):1447–1478.
 32. Hurst JR, Vestbo J, Anzueto A, et al; Evaluation of COPD Longitudi-
nally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investiga-
tors. Susceptibility to exacerbation in chronic obstructive pulmonary 
disease. N Engl J Med. 2010;363(12):1128–1138.
International Journal of COPD 2017:12 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2187
Outcomes in COPD patients with tidal eFl
 33. Jenkins CR, Jones PW, Calverley PM, et al. Efficacy of salmeterol/
fluticasone propionate by GOLD stage of chronic obstructive pulmonary 
disease: analysis from the randomised, placebo-controlled TORCH 
study. Respir Res. 2009;10:59.
 34. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and out-
comes of diabetes, hypertension and cardiovascular disease in COPD. 
Eur Respir J. 2008;32(4):962–969.
 35. de Bisschop C, Marty ML, Tessier JF, Barberger-Gateau P, Dartigues JF, 
Guénard H. Expiratory flow limitation and obstruction in the elderly. 
Eur Respir J. 2005;26(4):594–601.
 36. Koulouris NG, Valta P, Lavoie A, et al. A simple method to detect 
expiratory flow limitation during spontaneous breathing. Eur Respir J. 
1995;8(2):306–313.
 37. Crim C, Celli B, Edwards LD, et al; ECLIPSE investigators. Respi-
ratory system impedance with impulse oscillometry in healthy and 
COPD subjects: ECLIPSE baseline results. Respir Med. 2011;105(7): 
1069–1078.
 38. O’Donnell DE, Bertley JC, Chau LK, Webb KA. Qualitative aspects 
of exertional breathlessness in chronic airflow limitation: pathophysio-
logic mechanisms. Am J Respir Crit Care Med. 1997;155(1):109–115.
 39. GlaxoSmithKline. Evaluation of COPD (Chronic Obstructive Pul-
monary Disease) to Longitudinally Identify Predictive Surrogate 
Endpoints (ECLIPSE). Available from: https://clinicaltrials.gov/show/
NCT00292552?. NLM identifier: NCT00292552. Accessed April 4, 
2017.
International Journal of COPD
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal
The International Journal of COPD is an international, peer-reviewed 
journal of therapeutics and pharmacology focusing on concise rapid 
reporting of clinical studies and reviews in COPD. Special focus is given 
to the pathophysiological processes underlying the disease, intervention 
programs, patient focused education, and self management protocols. 
This journal is indexed on PubMed Central, MedLine and CAS. The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
International Journal of COPD 2017:12submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
2188
aarli et al
Supplementary materials
Table S1 Baseline characteristics in men and women (n=425)
Subject characteristics Total Men Women P-value
subjects (n) 425 254 171
age (years) 63 (7) 64 (7) 62 (7) 0.014
BMI kg/m2 25 (5) 26 (5) 25 (6) ns
Pack-years (years) 41 (23) 45 (24) 33 (18) ,0.001
mMrC 1.6 (1, 2) 1.6 (1, 2) 1.7 (1, 2) ns
FeV1 (l) 1.5 (0.5) 1.6 (0.6) 1.3 (0.4) ,0.001
FeV1 (%) 46 (14) 45 (14) 48 (13) 0.007
FVC (l) 3.3 (0.9) 3.7 (0.8) 2.6 (0.6) ,0.001
∆Xrs (kPa⋅s⋅l−1) 0.14 (0.17) 0.13 (0.14) 0.16 (0.20) ns
Note: Data presented as mean (standard deviation) unless otherwise stated.
Abbreviations: Uln, upper limit of normal 0.09 kPa⋅s⋅l−1; eFlT, tidal expiratory flow limitation; BMI, body mass index; Pack-years, packs of 20 cigarettes smoked per day × 
years as a smoker; Frequent exacerbators, percentage with $2 exacerbations the year the prior to inclusion; mMRC, modified Medical Research Council dyspnea scale 
score – mean (quartiles); FeV1, forced expiratory volume in 1 second; FeV1 (%), FeV1 percentage of predicted; FVC, forced vital capacity; IC, inspiratory capacity; IC (%), IC 
percentage of predicted; ∆Xrs, difference between mean inspiratory and mean expiratory reactance at 5 hz over multiple breaths; 6MWD, 6-minute walk distance.
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Figure S1 scatterplot of ∆Xrs plotted against FeV1 % predicted in healthy controls (n=229). Mean represented by the solid line. The dashed line represents the 97.5th 
percentile, the upper limit of normal (Uln).
